Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Ethical Dilemmas in Substance Use Disorders (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about ethical principles that can be applied to patient case discussions from 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Ethical issues have become more prominent in caring for patients with addiction, with stigma contributing. Perceptions of substance use disorder as a patient choice continue to taint appropriate medical for patients with substance use disorders. Clinical dilemmas arise related to "difficult" patients, "manipulative" behavior, refusal of care (by patients and providers) and legal issues. The workshop will initially review the ethical principles of autonomy, beneficence, non-maleficence, justice, fidelity and futility, The understanding of these concepts will then be applied to patient case discussions.  Scenarios will include patients making perceived "poor choices", specialist refusal of care, "mandated" treatment, and organ transplantation in patients with substance use disorder. Participants will join small groups to discuss each patient scenario and develop an answer (there may not be just one right answer).  Participants will also have an opportunity to present their own patient dilemmas that pose ethical questions.  The session will help build clinical confidence, by building skill to make decisions in clinical situations using an ethical framework.




    Learning Objectives:

    1.) Upon completion, participants will be able to understand ethical principles in medical care
    2.) Upon completion, participants will be able to demonstrate the ability to make decisions using an ethical framework
    3.) Upon completion, participants will be able to educate colleagues on providing ethical care to patients with substance use disorder 



    Michael Fingerhood

    MD, FACP

    Dr. Michael Fingerhood is an Associate Professor of Medicine at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance abuse treatment with primary medical care, including care for HIV and hepatitis C.

    Megan Buresh

    MD

    Dr. Megan Buresh is an Assistant Professor of Medicine and Epidemiology at the Johns Hopkins University School of Medicine.  She is board certified in internal medicine and addiction medicine and certified as AAHIVM HIV Specialist.  She received a Bachelor of Arts in Biochemical Sciences from Harvard University (magna cum laude with highest honors in field), completed medical school at Johns Hopkins University School of Medicine and residency at Brigham and Women’s Hospital.  She is the Secretary of the Maryland-DC ASAM Chapter. She is medical director of the Johns Hopkins Bayview Inpatient Addiction Consult Service.  She also provides integrated buprenorphine treatment as part of her outpatient primary care practice.  She is lead physician for BHLI PCARE, a mobile buprenorphine clinic for patients being released from Baltimore City Jail.  Her research interests include public health and addiction, developing and evaluating models to expand office-based opioid treatment, and improving linkages between clinical addiction treatment and community organizations.  She is a co-investigator with the ALIVE study at the Johns Hopkins Bloomberg School of Public Health, where she is studying risk factors for opiate overdose and access to naloxone among persons who inject drugs.    

    Jarratt D. Pytell

    MD

    Jarratt Pytell, M.D., is the 2018-19 fellow in Addiction Medicine at Johns Hopkins. He received his undergraduate degree from the University of Colorado at Boulder in mathematics and psychology. Afterwards he was accepted into Teach For America and worked as a 7th and 8th grade math teacher at a public school located in New Orleans' Upper Ninth Ward. He then earned his medical degree from Louisiana State University Health Sciences Center, New Orleans. During medical school, he was accepted as an Applied Epidemiology Fellow at the Centers For Disease Prevention and worked for a year in the Division of Waterborne Diseases. He completed his medical residency at Johns Hopkins Bayview Medical Center. He will complete a General Internal Medicine fellowship at Johns Hopkins after completing his Addiction Medicine fellowship and plans to pursue a career in academic medicine focusing on the primary care treatment of substance use disorders and address health disparities in access to substance abuse treatment.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Medical Management of Patients that Use Cannabis (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about cannabis use and cannabis addiction in patients who present for the treatment of psychiatric conditions and addictive diseases from 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    A firm understanding of the association between cannabis use, addiction to cannabis and/or other substances, and psychiatric symptoms and conditions is critical to the modern practice of addiction medicine. The prevalence of cannabis use is expected to increase in light of ongoing regulatory changes permitting the legal sale and use of cannabis. Additionally, cannabis use is more frequently used by individuals with the diagnosis of addiction. There is a well-documented association between cannabis use and several psychiatric sequelae. Therefore, patients who come to the attention of addiction physicians are increasingly likely to use cannabis. This presentation is designed to prepare clinicians to provide addiction medical management in patients who also use cannabis. This presentation will be divided into three sections. First, the presenters will briefly review the literature related to cannabis use and several psychiatric conditions. The presenters will provide a sample patient handout that summarizes the relevant therapeutic and repercussive correlations of cannabis use, which is useful for patient psychoeducation. Second, the presenters will review the recent research findings related to the treatment of cannabis and other addictive disorders. Third, the presenters will facilitate an interactive discussion of four sample cases of patients who present for non-cannabis addiction treatment but disclose using cannabis regularly. Examples of these cases will include: 1) a 45-year-old who uses cannabis daily and seeks treatment for excessive prescription opioid use; 2) a 22-year-old college student who uses cannabis daily and seeks treatment for anxiety and impairing alcohol use; 3) a 45-year-old veteran who uses cannabis daily and seeks treatment for anger outbursts and alcohol addiction, 4) and a 17-year-old adolescent who uses cannabis regularly and brought by his parents for chronic irritability and stimulant abuse. During these cases, the presenters will review and demonstrate motivational interviewing techniques, including how to use of the brief negotiated interview when patients present with co-occurring cannabis use. The workshop will conclude with an open discussion of these cases and a period of question and answer by audience participants.  By the conclusion of the workshop, participants will have a stronger understanding of the importance of addressing cannabis use and cannabis addiction in patients who present for the treatment of psychiatric conditions and addictive diseases.  




    Learning Objectives:

    1.) Describe the association between cannabis use, addiction involving cannabis and other substances, and psychiatric symptoms and conditions.
    2.) Develop an addiction medicine and/or psychiatric treatment plan for patients that use cannabis who have a substance use disorder and/or other psychiatric condition.
    3.) Apply a motivational interviewing technique as part of a conversation related to changing cannabis use with patients.



    Iman Parhami

    MD, MPH

    Iman Parhami, MD, MPH is a double-board certified child and adolescent psychiatrist focused on addictions. Dr. Parhami currently sees adult patients at a LA County's community mental health clinic, where he is also the co-leader of the Co-Occurring Disorders Clinic. In addition, he is the psychiatrist for two residential treatment centers for adolescents with substance use problems and he sees patients at USC's University Center for Excellence in Developmental Disabilities at Children's Hospital of Los Angeles. 

    Dr. Parhami completed his child and adolescent psychiatry fellowship at Johns Hopkins University and his adult psychiatry residency at Delaware's State program. During his training, he received multiple national recognition awards, which included a research training grant from the American Academy of Children and Adolescents and National Institute of Drug Use, and other awards from the American Academy of Addiction Psychiatry and American Psychiatric Association. Dr. Parhami has published multiple peer-reviewed scientific journal articles focusing on addictive disorders. Notably, Dr. Parhami completed a postdoctoral research fellowship at UCLA focusing on psychosocial interventions for behavioral addictions and a clinical fellowship at the Psychoanalytic Center of Philadelphia.

    Marissa Andres-Kim

    MD

    Marissa Andres-Kim, MD, is a board certified psychiatrist, who completed her residency at the Harbor-UCLA Medical Center after graduating from the University of California Davis School of Medicine.  She works at a community mental health center for the Los Angeles County’s Department of Mental Health, where she treats patients for general psychiatric disorders, including substance use, in English, Spanish, and Tagalog.  With Dr. Iman Parhami, Dr. Andres-Kim established a Co-Occurring Disorders Sub-Clinic and Multi-Disciplinary Team that is focused on improving the delivery of addiction treatment in a community setting.  At her clinic, she is also the lead for the Dialectical Behavioral Therapy team that works with patients with Borderline Personality Disorder, including those with co-morbid substance use.  Outside of her clinic, Dr. Andres-Kim is a volunteer faculty member at the New Center for Psychoanalysis in Westwood and regularly teaches a seminar on Object Relations Theory.  Dr. Andres-Kim is focused on providing effective clinical care to patients as well as enhancing the strengths of those who work with her.  Outside of work, she also enjoys visiting national parks with her family, taking photos, and playing the accordion.

    Brian Hurley

    MD, MBA, DFASAM

    Dr. Brian Hurley is an addiction psychiatrist and Medical Director for Co-Occurring Disorder Services for the Los Angeles County Department of Mental Health (LACDMH), supporting the identification and management of co-occurring substance use among patients with mental illness served by LACDMH. He is an assistant professor of Addiction Medicine at UCLA. 

    Brian serves as the Treasurer and is a Distinguished Fellow of the American Society of Addiction Medicine. Brian joined ASAM in 2002 as a first year medical student, and has served on the ASAM Board of Directors in various capacities since 2003. Brian previously served as chair of ASAM’s Membership Committee and Physicians-in-Training Committee and is formerly ASAM’s alternate delegate to the American Medical Association. Brian additionally served on the EVP/CEO search committee in 2010 that led to Penny Mill’s selection as ASAM’s current EVP/CEO. He has additional served in various roles for the Massachusetts Society of Addiction Medicine, New York Society of Addiction Medicine, and California Society of Addiction Medicine.

    Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA), and was previously a Veterans Administration National Quality Scholar at the VA Greater Los Angeles Healthcare System. He completed residency training at the Massachusetts General Hospital and McLean Hospital, where he was Chief Resident in Addiction Psychiatry and addiction psychiatry fellowship training at Bellevue Hospital and the New York Veterans Administration. Brian is a graduate of the Keck School of Medicine and Marshall School of Business of the University of Southern California. He was a 2012 American College of Psychiatrists Laughlin fellow, a 2010-2013 American Psychiatric Association (APA) Public Psychiatry Fellow, and a 2015-2017 Group for Advancement of Psychiatry Fellow. Brian has previously served on the Board of Trustees of the APA.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • The Addiction Dungeon: Journey of Addicted Women Through Maslow’s Hierarchy of Needs (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about Maslow's hierarchy of needs and how it can be implemented with recovery from The ASAM 50th Annual Conference (2019).

    Addictive disorders carry the risk of severe functional decline, while abstinence is usually accompanied by improvement in functional status, and a more consistent ability to get needs met; however, substance users struggle with conceptualizing their journey and future planning. Some evidence suggests Maslow’s Hierarchy can be helpful for psychological health and belief in internal control. There is little research on its direct application to substance use and recovery. In this workshop, we present a narrative, case-linked journey of women with addiction: along the way, we will discuss conceptualization of sobriety and/or abstinence and relapses in terms of Maslow’s hierarchy of needs. We will review the steps and goals of each stage of the hierarchy, which are physiological, safety, belonging/love, self-esteem, and self-actualization. We then introduce a concept coined by our patients in recovery: the addiction dungeon, which our users defined as the level below Maslow’s basic starting point. We will discuss the element of confinement and lack of choice or free will in situations such as imprisonment, involuntary commitment and other confined situations. Lack of free will eliminates the element of internal control, which we seek to help our patients attain. By removing internal control in confinement, those in recovery become blocked from self-actualization. In this workshop (sections below), we will introduce a modified Maslow’s Hierarchy, including the addiction dungeon, as a therapeutic tool to help patients set goals in recovery, and to better address the challenges associated with each level. 1. Maslow’s hierarchy: how does the path to self-actualization apply to women with addiction? 2. Narrative focus group results: presented by two student winners of the prestigious Albert Schweitzer fellowship, describing how women in rehab perceive their experiences with confinement. 3. Clinical applications of modified Maslow’s hierarchy: link to commonly used therapeutic modalities such as cognitive behavioral therapy and motivational interviewing.

    (1 CME) In this conference recording from the 2019 Annual Conference, you will learn:


    Learning Objectives:

    1.) Understand basic requirements of passing through the stages of Maslow’s Hierarchy
    2.) Have a general understanding of how Maslow’s Hierarchy can be applied to addiction
    3.) Learn about the impact of lack of free will leading to a new stage prior to Stage 1 of the hierarchy


    Nancy C. Shenoi

    Medical Student

    Nancy Shenoi is a fourth-year medical student at Baylor College of Medicine pursuing a career in psychiatry. She is interested in academic medicine, addiction psychiatry, and women’s mental health. With support from the Albert Schweitzer Fellowship, Nancy and her medical student colleague Maria Espinosa led health literacy and mental health workshops for women with substance use disorders at a state-funded residential rehab facility in Houston, Texas.

    Kimberly Parks

    MD

    Kimberly Parks, MD is an Assistant Professor of Psychiatry at Baylor College of Medicine where she is both a general and addiction psychiatrist. She recently graduated from the Baylor College of Medicine Addiction Psychiatry Fellowship and previously completed her general psychiatry residency at University of Southern California/Los Angeles County + USC Medical Center. Currently, she works at Ben Taub General Hospital in both the Substance Abuse Treatment Clinic and the Psychiatric Emergency Department. She is also a new addition to the Baylor Psychiatry Clinic where she is offering substance use treatment. She is passionate about the treatment of substance use disorders, resident education and women’s mental health.

    Nidal Moukaddam

    MD

    Nidal Moukaddam, MD PhD, Associate Professor at Baylor College of Medicine, is involved in clinical addiction medicine, education and research. Dr. Moukaddam’s interests include three distinct areas i)Scalable Health: the application of technology to mental health ii) Sociability and social ambiance automated measurements and iii) Instant countertransference (iCT) . The bulk of her work as a clinician revolves around difficult patients, those who have trouble getting care in traditional settings. Dr. Moukaddam's research interest focus on how psychiatry can benefit from technological advances for detection, tracking, diagnosis and treatment of mental illness & addiction. Prior efforts have led to the co-creation of a fee-free, dynamic platform for academic collaboration, Healthsense, that is available for researchers wishing to engage in sensor-based measurements in their studies. i) Scalable health: the application of technology to mental health. This is an area of collaboration with Rice University, Electrical and Computer Engineering department, which has produced innovative, cutting edge research into the applicability of measuring mental states objectively using smartphone applications. ii) Sociability and social ambiance automated measurements: the quantity and quality of connection between individuals determines the feelings of well-being and loneliness. Our aim as a research team has been to find ways to accurately and objectively measure an individual’s interactions, and quantify their ambiance in ways that can be used for psychiatric treatment. iii) Instant countertransference (iCT): this is a concept developed to bridge the gap between the notion of bias in healthcare, and the traditional psychiatric concept of countertransference. Looking for a flexible, nuanced explanation for how subjective clinician feelings can impact medical decisions. It is the answer of many years of experience in multidisciplinary work with emergency medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • The ASAM Pain & Addiction: Common Threads XX 2019 (8 CME)

    Contains 11 Product(s)

    Participants will learn clinical best practices and new research developments for treating patients with pain and addiction and how to begin to integrate these techniques into their own practices.

    OVERVIEW

    The ASAM Pain & Addiction: Common Threads Course is one of ASAM's longest running and most popular courses. This course is designed to develop learners' clinical skills and improve treatment of patients who fall somewhere in the gray area around pain and addiction. Participants will learn clinical best practices and new research developments affecting treatment and how to integrate these techniques into their own practices. This year's course will examine complex and challenging patient cases and identify next steps to treatment.

    LEARNING OBJECTIVES

    Upon completion of this educational activity, participants should be able to:

    1. List 5 ways that trauma can impact a patient’s pain and/or addiction.
    2. Create a script for communicating with patients about challenging clinical issues such as buprenorphine cessation or opioid induced hyperalgesia.
    3. Evaluate current research on non-pharmacologic therapies for pain and identify which may be useful with their patients.
    4. Develop a peri-operative treatment plan for patients on agonist and antagonist medications that reflects the current research and coordinates care with other members of the team.
    5. Identify methods to address acute pain in a chronic pain patient and methods to transition back after an instance of acute pain.
    6. Explain indications, risks, and benefits for tapering or discontinuing buprenorphine.
    7. Analyze current research on cannabis use in patients with pain and communicate that information to patients.
    8. Describe the recent data, risks, benefits, and indications for using gabapentinoids while treating patients with pain.
    9. Explain the relationship between pain, sleep, and addiction. Identify effects that key drugs play on sleep and the risks that creates.

    This course is intended for those in the addiction medicine field who already have some experience with pain and addiction. Other healthcare providers and members of the care team interested in treating this patient population are also encouraged to attend.

    Upon completion of this educational activity, participants should be able to:

    1. List 5 ways that trauma can impact a patient’s pain and/or addiction.
    2. Create a script for communicating with patients about challenging clinical issues such as buprenorphine cessation or opioid induced hyperalgesia.
    3. Evaluate current research on non-pharmacologic therapies for pain and identify which may be useful with their patients.
    4. Develop a peri-operative treatment plan for patients on agonist and antagonist medications that reflects the current research and coordinates care with other members of the team.
    5. Identify methods to address acute pain in a chronic pain patient and methods to transition back after an instance of acute pain.
    6. Explain indications, risks, and benefits for tapering or discontinuing buprenorphine.
    7. Analyze current research on cannabis use in patients with pain and communicate that information to patients.
    8. Describe the recent data, risks, benefits, and indications for using gabapentinoids while treating patients with pain.
    9. Explain the relationship between pain, sleep, and addiction. Identify effects that key drugs play on sleep and the risks that creates.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • The Role of the Hospital in the 21st Century Opioid Overdose Epidemic: The Addiction Medicine Consult Service (1 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more the role hospitals play in the overdose epidemic from this journal article from The Journal of Addiction Medicine 2019.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about the role hospitals lay in the overdose epidemic from this journal article from The Journal of Addiction Medicine 2019. Kelsey C. Priest, MPH, Dennis McCarty, PhD

    Learning objectives: 

    1.) Identify the commonalities and differences in organizational structure and design of U.S addiction medicine consult (AMC) services. 

    2.) Describe the primary responsibilities of AMC services.

    3.) Recognize potential policy levers for increasing or promoting hospital-based services for patients with OUD and other SUDs.


  • Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations (1 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about buprenorphine pharmacology from this journal article from The Journal of Addiction Medicine 2019.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about buprenorphine pharmacology in this journal article from The Journal of Addiction Medicine 2019. Sharon L. Walsh, PhD, Marion A. Coe, BA, Michelle R. Lofwall, MD

    Learning objectives: 

    1.) Explain how aspects of buprenorphine pharmacology (of both transmucosal and long-acting formulations) manifest its clinical effects

    2.) Provide an explanation of the differences in dose exposure provided by the different buprenorphine formulations

    3.) Define potency with a clinical example


  • How to Track Treatment Progress and Adherence with the ASAM Criteria

    Contains 1 Component(s)

    Learn more about tracking treatment progress, ensuring participants adhere to medication in addiction from this recorded webinar from Dr. David Mee-Lee

    Join Dr. David Mee-Lee, leading expert in substance use disorder treatment and Chief Editor of The ASAM Criteria®, for an informative webinar that will aid drug court team members in tracking treatment progress and ensuring that participants adhere to medication in addiction treatment.  This webinar, which is jointly sponsored by the National Association of Drug Court Professionals and the American Society of Addiction Medicine, is designed especially for judges, coordinators, prosecutors, defense attorneys, supervision officers, case managers, and other team members who refer, monitor, or otherwise support behavioral health treatment in drug courts.


    Participants will:

    1. Review the definition of addiction and the use of medication in addiction treatment.

    2. Recognize the stages of change and appropriate treatment for each stage. Address issues of compliance versus adherence—”doing time” versus “doing treatment and change.”

    3. Identify procedures to ensure treatment adherence, including communication among the interdisciplinary drug court team, quality and content of treatment provider reports, and the use of random drug testing.


    David Mee-Lee

    MD, FASAM

    David Mee-Lee, M.D. is a board-certified psychiatrist, and is certified by the American Board of Addiction Medicine (ABAM). Based in Davis, California, he trains and consults both nationally and internationally.  Dr. Mee-Lee is Chief Editor of the American Society of Addiction Medicine's (ASAM) Criteria for the Treatment of Addictive, Substance-Related, and Co-Occurring Conditions and is President of DML Training and Consulting. He is co-founder of the Institute for Wellness Education. Dr. Mee-Lee has forty years of experience in person centered treatment and program development for people with co-occurring mental health and substance use conditions.

  • Changes in Healthcare Encounter Rates Possibly Related to Cannabis or Alcohol following Legalization of Recreational Marijuana in a Safety-Net Hospital: An Interrupted Time Series Analysis (1 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about adverse healthcare encounters with cannabis related instances since the legalization of cannabis from The Journal of Addiction Medicine 2019.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about adverse healthcare encounters with cannabis related instances since the legalization of cannabis in this journal article from The Journal of Addiction Medicine 2019. Susan L. Calcaterra, MD, MPH, Christian J. Hopfer, MD, Angela Keniston, MSPH, and Madelyne L. Hull, MPH


    Learning objectives: 

    1.) Examine characteristics of patients with healthcare encounters possibly related to cannabis

    2.) Assess the temporal association between legalization of recreational marijuana and healthcare encounters possibly attributed to cannabis


  • The ASAM Treatment of Opioid Use Disorder Course 8-Hour Online

    Contains 6 Component(s), Includes Credits

    This course covers all approved medications to treat opioid use disorder and provides the 8 hours of education needed to receive a waiver to prescribe buprenorphine in an office-based setting.

    image

    8-Hour Online Course for Physicians*

    Welcome to The ASAM Treatment of Opioid Use Disorder Course. This course provides 8 hours of education needed for physicians  to receive a waiver to prescribe buprenorphine in an office-based setting. More information on waiver requirements can be found on the SAMHSA website.

    To begin the online course, please log-in to your left and locate the box that says, "Module 1" in the "Contents" tab. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

    All online modules and quizzes must be completed before you can claim credit for the course. Detailed instructions for completing the  course can be found under the tab titled, "Course Instructions."

    After completing the online modules, corresponding quizzes, and applicable evaluations, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    *NPs, PAs, CNMs, CRNAs, and other CNSs are required to complete no less than 24 hours of training. ASAM offers 24 hour packages for free. Click here for more information.

    Note: Resident & Fellow ASAM Members (in training) receive complimentary access to the 8-hour online ASAM Treatment of Opioid Use Disorder Course. Click here to become a member. Please note membership approval requires up to two business days.

    Daniel P. Alford

    MD, MPH, FACP, DFASAM

    Dr. Daniel P. Alford is an Associate Professor of Medicine, Assistant Dean of CME and Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine. He is a diplomate in Addiction Medicine by the American Board of Addiction Medicine (ABAM).

    He is director of the Clinical Addiction Research and Education Unit medical director of the Office-Based Opioid Treatment (OBOT) program and of the Massachusetts Screening, Brief Intervention, Referral to Treatment Training and Technical Assistance (MASBIRT TTA) program and former program director for the Addiction Medicine Fellowship program at Boston Medical Center (BMC). Since 2001 he has served as the course director of the Chief Resident Immersion Training (CRIT) Program in Addiction Medicine: Improving Clinical and Teaching Skills for Generalists funded by NIDA. He is president of the Association for Medical Education and Research in Substance Abuse (AMERSA). In 2011, he was recognized as a Champion of Change by the White House. In 2014 he received the Health Education Award from the American Medical Association.

    R. Corey Waller

    MD, MS, DFASAM

    R. Corey Waller, MD, MS, FACEP, DFASAM, is an addiction, pain and emergency medicine specialist. Dr. Waller earned his bachelor's degree in biology and his master's degree in neuromolecular biology at Southwest Texas State University in San Marcos, Texas. He earned his medical degree at University of Texas Medical School in San Antonio. Dr. Waller completed his emergency medicine residency at Thomas Jefferson University in Philadelphia. He is board certified and fellowship trained in addiction medicine.

    Debra Newman

    PA-C, MPAS, MPH

    Debra R. Newman, PA-C, MPAS, MPH currently serves as treatment provider for First Judicial District Court, Adult Drug Court for Santa Fe and Rio Arriba Counties, New Mexico. Debra has worked in residential treatment as well as out-patient adult psychiatry and addiction medicine. Her passion for addiction medicine began with her association with Project ECHO in 2008. While employed at an FQHC in northern NM in a region historically plagued with the highest per capita heroin death rate in the nation, Debra worked under an addiction medicine psychiatrist and several family practice physicians waivered to prescribe buprenorphine. For over four years, she managed over 200 buprenorphine patients monthly, as the only full-time provider for these patients, while also carrying a caseload of HCV and chronic pain patients. She is currently working with the PA Foundation and NIDA on a grant examining the role of PA’s in drug courts.

    Marian Currens

    Associate Director, University of Maryland Medical Center Midtown Campus

    Marian Currens, CRNP is located in Baltimore, MD.

    Learning Objectives:

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorder
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorder
    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorder
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorder
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorder
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder
    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    CME Information and Disclosure Listing

    Date of Release: June 2018 

    Approved Through: December 2020

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAMNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received? Stock 
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVS None
    Tricia E. Wright, MD, MS, FACOG, DFASAM None


    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD (Chair)None
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRONone
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Sandy MetcalfeNone


    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartNone

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies no less than 8 hours of training is necessary for physicians to obtain a waiver to engage in office-based treatment of opioid use disorder using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    For 24-Hour Treatment of Opioid Use Disorder Course issuing AANP CE Credit: Click Here

    For 24-Hour Treatment of Opioid Use Disorder Course issuing AAPA Category 1 CME Credit or AMA PRA Category 1 CME Credit: Click Here


    This training is divided into two parts of 8 hours and 16 hours. If you have already completed the 8-hour DATA2000 course, you will only need to complete the second part of the 16-hour course.

    Legislation
    Comprehensive Addiction and Recovery Act (CARA)
    ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    HR6 - SUPPORT for Patients and Communities Act
    HR6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, added qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives to list of practitioners eligible to prescribe buprenorphine until October 1, 2023. The ASAM Treatment of Opioid Use Disorder Course is available for qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives.

    Qualify
    To qualify for a waiver, NPs, PAs, CRNAs, CNMs, and CNSs must:

    • Be licensed under state law to prescribe Schedule III, IV, or V medications for pain
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver. 

    1. Providers who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
    2. Clinicians and healthcare team members working with providers who prescribe buprenorphine in office-based treatment of opioid use disorders.

    ASAM would like to acknowledge the following supporters:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI026793-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Staten Island, NY - Thursday, September 19, 2019

    Contains 8 Component(s), Includes Credits

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

        

    image


    Thursday, September 19, 2019 | 9:00 am - 1:30 pm

    South Beach Psychiatric Center
    777 Seaview Avenue
    Administrative Building, 2nd Floor, TV Studio
    Staten Island, NY 10305

    Hosted by NYDOH

    Online Portion Due: Wednesday, September 18, 2019

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    Getting started: To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."

     If you have any questions, please contact education@ASAM.org.

    1. Locate the box on the right that says “View Course" and click “View Course"
      1. A new window will open with the course. Be sure your pop-up blocker is turned off.
    2. Complete Module 1 and Module 2 (equivalent to four hours of instruction)
    3. You will be required to pass all CME Quizzes with a grade of 70% or higher
    4. Upon completion of both the two online modules and four hours of live, in-person instruction, you will be able to claim CME credit through the ASAM e-Learning Center




    Learning Objectives

    Module 1

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    CME Information and Disclosure Listing

    Date of Release: July 2015 

    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone


    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

      HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

      NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:




      If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.


    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.